202 related articles for article (PubMed ID: 21654838)
21. Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells.
Prasmickaite L; Skrbo N; Høifødt HK; Suo Z; Engebråten O; Gullestad HP; Aamdal S; Fodstad Ø; Maelandsmo GM
Pigment Cell Melanoma Res; 2010 Jun; 23(3):449-51. PubMed ID: 20236249
[No Abstract] [Full Text] [Related]
22. Cancer stem cell as therapeutic target for melanoma treatment.
Alamodi AA; Eshaq AM; Hassan SY; Al Hmada Y; El Jamal SM; Fothan AM; Arain OM; Hassan SL; Haikel Y; Megahed M; Hassan M
Histol Histopathol; 2016 Dec; 31(12):1291-301. PubMed ID: 27301538
[TBL] [Abstract][Full Text] [Related]
23. Melanoma: do we need a hatchet or a scalpel?
Shackleton MJ; Quintana E; Fullen DR; Sabel MS; Johnson TM
Arch Dermatol; 2009 Mar; 145(3):307-8. PubMed ID: 19289763
[No Abstract] [Full Text] [Related]
24. Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment.
Ascierto PA; Mozzillo N; Caracò C; Parasole R; Palmieri G; Melucci MT; Botti G; Castello G
Ann Oncol; 2000 Nov; 11(11):1504. PubMed ID: 11142495
[No Abstract] [Full Text] [Related]
25. Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.
Grasso C; Anaka M; Hofmann O; Sompallae R; Broadley K; Hide W; Berridge MV; Cebon J; Behren A; McConnell MJ
BMC Cancer; 2016 Sep; 16(1):726. PubMed ID: 27613604
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
[TBL] [Abstract][Full Text] [Related]
27. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
28. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Luo Y; Dallaglio K; Chen Y; Robinson WA; Robinson SE; McCarter MD; Wang J; Gonzalez R; Thompson DC; Norris DA; Roop DR; Vasiliou V; Fujita M
Stem Cells; 2012 Oct; 30(10):2100-13. PubMed ID: 22887839
[TBL] [Abstract][Full Text] [Related]
29. Cellular heterogeneity in vertical growth phase melanoma.
Laga AC; Murphy GF
Arch Pathol Lab Med; 2010 Dec; 134(12):1750-7. PubMed ID: 21128771
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cells versus phenotype-switching in melanoma.
Hoek KS; Goding CR
Pigment Cell Melanoma Res; 2010 Dec; 23(6):746-59. PubMed ID: 20726948
[TBL] [Abstract][Full Text] [Related]
31. Spheres of influence in cancer stem cell biology.
Perego M; Alison MR; Mariani L; Rivoltini L; Castelli C
J Invest Dermatol; 2011 Feb; 131(2):546-7. PubMed ID: 20962857
[No Abstract] [Full Text] [Related]
32. Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review.
Kyriakou G; Melachrinou M
Future Oncol; 2020 Jul; 16(21):1549-1567. PubMed ID: 32484008
[TBL] [Abstract][Full Text] [Related]
33. The combination of bleomycin with suicide or interferon-β gene transfer is able to efficiently eliminate human melanoma tumor initiating cells.
Fondello C; Agnetti L; Villaverde MS; Simian M; Glikin GC; Finocchiaro LME
Biomed Pharmacother; 2016 Oct; 83():290-301. PubMed ID: 27399807
[TBL] [Abstract][Full Text] [Related]
34. Location, location, location: Melanoma cells "living at the edge".
Maiques O; Sanz-Moreno V
Exp Dermatol; 2022 Jan; 31(1):82-88. PubMed ID: 34185923
[TBL] [Abstract][Full Text] [Related]
35. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
36. Lessons from cancer immunoediting in cutaneous melanoma.
Aris M; Barrio MM; Mordoh J
Clin Dev Immunol; 2012; 2012():192719. PubMed ID: 22924051
[TBL] [Abstract][Full Text] [Related]
37. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
38. Cancer stem cells: distinct entities or dynamically regulated phenotypes?
Li Y; Laterra J
Cancer Res; 2012 Feb; 72(3):576-80. PubMed ID: 22298594
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.
Kumar D; Gorain M; Kundu G; Kundu GC
Mol Cancer; 2017 Jan; 16(1):7. PubMed ID: 28137308
[TBL] [Abstract][Full Text] [Related]
40. A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human disease.
Sun Q; Lee W; Mohri Y; Takeo M; Lim CH; Xu X; Myung P; Atit RP; Taketo MM; Moubarak RS; Schober M; Osman I; Gay DL; Saur D; Nishimura EK; Ito M
Nat Commun; 2019 Nov; 10(1):5023. PubMed ID: 31685822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
